Diagnostic advances bode well for the imminent expansion of the global COVID-19 detection kits market, which is expected to be worth $8 billion by 2027.
Greater use of next generation sequencing can better prepare the world for future diseases and accelerate the adoption of precision care.
During the COVID-19 crisis, digital forces like artificial intelligence have assisted the healthcare industry to focus on patient care while achieving improved efficiency during treatments.
Anyone can read the regulation. The challenge is in how to apply it to your company’s structure and product line.
The PCR and real-time PCR molecular diagnostics was valued at $4 billion in 2019.
Part one of this series looks at the claims brought against manufacturers of diagnostic test kits.
In order to meet the worldwide need for faster and affordable testing processes, companies must shift goals and apply resources to ending this pandemic.
The authorization is a step toward broad screening that will help reopen schools and workplaces in America, says FDA Commissioner Stephen Hahn, M.D.
Companies developing technologies that integrate AI need to consider regulatory concerns, community demographics, fitting into existing workflows, technical proficiency of both the hospital personnel and consumers.
The winning innovators will receive grant awards of upwards of $50,000.